Unlocking a New Era in Research & Development: IQVIA Welcomes Richard Staub III as President of Research & Development Solutions

In a strategic move that promises to redefine the landscape of advanced analytics, technology solutions, and clinical research services for the life sciences industry, IQVIA™ (NYSE:IQV) has unveiled its new President of Research & Development Solutions (R&DS) business unit – the seasoned industry veteran, Richard Staub III.

With a remarkable 34-year journey in the life sciences sector, Richard brings a wealth of experience and visionary leadership to the forefront. Notably, he previously helmed the R&DS business unit at IQVIA from 2016 to 2022, overseeing a period of remarkable growth.

Under his astute guidance, the unit achieved unprecedented milestones, boasting consecutive years of record-breaking backlog, industry-leading book-to-bill ratios, and substantial revenue surges. His tenure also witnessed the rapid expansion of IQVIA’s clinical research capabilities, all while navigating the tumultuous waters of the COVID-19 global pandemic with unwavering resilience.

As the senior advisor to the Chairman and CEO of IQVIA, Richard played a pivotal role in ensuring the continued triumph of R&DS. His responsibilities ranged from nurturing key customer relationships to providing sage leadership on critical business matters and shaping the strategic trajectory of the organization.

In this momentous transition, Costa Panagos, a distinguished figure with a 24-year legacy at IQVIA, will be stepping into retirement. Costa’s contributions, including his leadership of the R&DS business unit since 2022, have left an indelible mark on the organization. IQVIA extends its heartfelt gratitude to him for his invaluable service.

This dynamic change signals the dawn of a new era for IQVIA™, where Richard Staub III takes the helm, poised to lead the charge towards unprecedented innovation and excellence in the life sciences industry.


In a world where healthcare meets cutting-edge technology, IQVIA (NYSE:IQV) stands as an unrivaled global force. Imagine a powerhouse that seamlessly weaves together advanced analytics, transformative technology, and clinical research services to empower the life sciences industry. IQVIA isn’t just a company; it’s the architect of intelligent connections that span the entire healthcare landscape.

At its core, IQVIA is the guardian of healthcare’s future, armed with big data resources and a treasure trove of domain expertise. The magic lies in IQVIA Connected Intelligence™, a symphony that delivers profound insights at lightning speed.

These insights aren’t just numbers; they are the keys to unlocking the clinical development and commercialization of groundbreaking medical treatments. It’s about reshaping healthcare, rewriting the rules, and ultimately, improving the lives of patients.

With a global family of around 87,000 passionate individuals, IQVIA doesn’t just operate in more than 100 countries; it transcends borders to pioneer a new era of healthcare. But it’s not just about numbers and locations; it’s about a mission.

IQVIA is on a quest to safeguard patient privacy, leveraging a dazzling array of privacy-enhancing technologies and safeguards. In doing so, it charts a path where data reveals disease patterns, and treatment becomes more precise, all while preserving individual privacy.

In essence, IQVIA is the silent hero, empowering biotech, medical device, and pharmaceutical companies. It fuels the aspirations of medical researchers, government agencies, payers, and all healthcare stakeholders. It offers a window into the very essence of diseases, human behavior, and scientific breakthroughs, paving the way for a future where cures are not just a dream, but a tangible reality.

Leave a Comment